$ARGS breakout. low float.
Nasdaq $3.33
Website
$ARGS breakout. low float.
Nasdaq $3.33
Website
Shares Outstanding: 20.74M
Float: 8.18M
% Held by Insiders: 59.17%
% Held by Institutions: 23.90%
Shares Short (as of Dec 31, 2015): 278.09K
Short Ratio (as of Dec 31, 2015) 2.04
Short % of Float (as of Dec 31, 2015): 3.72%
Shares Short (prior month): 212.57K
Headlines
Argos Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on Arcelis, its proprietary technology platform. Its development stage products include AGS-003, which is under Phase III clinical trials for the treatment of metastatic renal cell carcinoma and other cancers; and AGS-004, which is in phase 2 clinical trial for the treatment of Human Immunodeficiency Virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is headquartered in Durham, North Carolina.
Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Honoring Tradition and Service The good ol’ U.S. Postal Service is at it again, giving a tip of the hat to a slice of American military heritage. This time, they’re putting out a new stamp to celebrate the 150th anniversary of the U.S. Coast Guard Academy. And you know where they did the honors? Right there on Custom House Pier in New London, Connecticut, a place that...
Continue Reading
The Rise of "Safe Ground" on Prime Video This isn't your typical feel-good story—it’s about grit and the unending fight for 'normalcy' where war left scars. Safe Ground, now streaming on Prime Video, showcases Ryan Hendrickson, a U.S. Army Green Beret whose story takes a sharp turn after stepping on an IED in 2010. The day he almost became just another statistic...
Continue Reading
Trouble Brews at D-Wave Quantum Smack in the middle of market chaos, D-Wave Quantum Inc. (NASDAQ: QBTS) seems to have hit a rather gnarly pothole. With disappointing revenue figures for Q2 of 2026—coming in at a measly $3.08 million, far below the expected range of $4.03 million to $4.08 million—investors have more than enough reasons to be irked. When the numbers...
Continue Reading
Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...
Continue Reading
The Hidden Cost of Colorado's Dry Air Dry climate isn't just a seasonal inconvenience—it's a real hidden cost to living comfortably and healthily in Colorado. With winters colder than a brass monkey's tail and summers that don't offer much relief in terms of humidity, your home's air quality is on the front line. So, what's the financial tale here, and how do you come...
Continue Reading
The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...
Continue Reading
Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...
Continue Reading
Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...
Continue Reading
Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...
Continue Reading
Why Pizza Is More Than Just Food They say a slice of pizza can tell a story. Whether it's a late-night snack amongst college buddies or the centerpiece of a family's Friday tradition, pizza unites like few others can. It morphs from a study aid into a tool for togetherness without skipping a beat, much like a chameleon of the food world. And no one understands this better...
Continue Reading
Top 5 Most Recently Viewed Articles
Waller Backs Fed's Rate Adjustment Strategy In a recent conversation about the Federal Reserve's monetary policy, Board of Governors Member Christopher Waller provided insights into the FOMC's choice to cut interest rates by 50 basis points. This announcement drew considerable attention during an interview broadcasted on a well-known financial news channel. These remarks...
Continue Reading
BayCare Health System Welcomes Lynnette A. Clinton Lynnette A. Clinton has made a significant return to BayCare Health System, taking on the key role of Chief Information Officer (CIO). Having previously served as the vice president of applications, Clinton is recognized for her leadership skills and dedication to advancing healthcare technology. Leadership Role and...
Continue Reading
FLSmidth's Strategic Share Buy-Back Program FLSmidth & Co. A/S has embarked on a significant share buy-back initiative aimed at enhancing shareholder value and demonstrating confidence in its operational capabilities. The company, a leading supplier of technology and services to the global mining industry, announced a program that allows for the repurchase of shares up to...
Continue Reading
Patrick Industries Announces Dividend Increase Patrick Industries, Inc. (NASDAQ: PATK) recently revealed an increase in its quarterly cash dividend, a move that reflects the company's lasting commitment to its shareholders and the robustness of its operational model. This decision comes as part of the company's ongoing strategy to deliver rewarding returns to investors....
Continue Reading
Omega Healthcare Celebrates Recognition in RCM Services Omega Healthcare has been honored with the prestigious 2026 Best in KLAS award, distinguishing itself as a top performer in Ambulatory RCM Services. With an outstanding overall performance score of 92.2, this recognition marks a significant milestone for the company, reflecting its commitment to delivering...
Continue Reading